Dren Bio, Inc.

FOSTER CITY, CA · Founded 2019 · CIK 0001783374 · Biotech · Private

Engineered therapeutic antibodies for selective targeting and depletion of disease-causing cells and agents

drenbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$93M
3 Form D · Mar 2022
54 months since last filing
Contracts
—
No federal contracts on record
Patents
33
2 granted · 31 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,054,991
Private capital raisedForm D · SEC$25,499,996
Private capital raisedForm D · SEC$62,500,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2275EdenRoc Sciences LLC—$194M
2276ENGAGE BIOLOGICS INC.——
2277Perfect Day, Inc.—$222M
2278Dren Bio, Inc.—$93M
2279CURAVAC, INC.—$4.7M
2280bluebird bio—$179M
2281EFFECTORBIO, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Sakae AsanumaDirector
  • Rajeev DadooDirector
  • Alex KolicichDirector
  • Chandra LeoDirector
  • Kenneth LuehrsenDirector
  • Andrew SchiffDirector
  • Nenad TomasevicDirector · Executive Officer
  • Ivan TrifunovichDirector
  • John WesleyDirector

Patents

USPTO · 2 granted of 33
  • ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofapplication
  • Methods Of Depleting Disease Causing Agents Via Antibody Targeted Phagocytosisapplication
  • ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofgranted
  • ANTI-CD94 Antibodies And Methods Of Use Thereofgranted
  • Methods Of Reducing Large Granular Lymphocyte And Natural Killer Cell Levelsapplication
  • Methods Of Depleting Disease Causing Agents Via Antibody Targeted Phagocytosisapplication
  • Multispecific Antibodies And Methods Of Use Thereofapplication
  • ANTI-CD94 Antibodies And Methods Of Use Thereofapplication
  • Multispecific Binding Proteins That Bind DECTIN-1 And TROP-2 And Methods Of Use Thereofapplication
  • Multispecific Binding Proteins That Bind DECTIN-1 And CD20 And Methods Of Use Thereofapplication
  • ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofapplication
  • ANTI-CD94 Antibodies And Methods Of Use Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.